ARCH Venture Partners
Facts
- HQ
- Chicago
- Sectors
- Venture Capital, Life Sciences, Biotechnology, Technology
- Stage
- early-stage
Sana Biotechnology files IPO to raise up to $150M, aims to trade as SANA while advancing in‑body gene and cell therapies
Sana Biotechnology, founded less than three years ago with no revenue, filed to go public on Nasdaq under ticker SANA seeking to raise up to $150 million while developing gene and cell therapies aimed at controlling or modifying genes and treating cancers. The Seattle-area startup has raised over $700 million in venture funding, held $459 million in cash and equivalents at September-end, but carries a $316 million accumulated deficit.
CityBldr CEO Bryan Copley Battled COVID-19 in March While Running His $6M Seattle Startup in Capitol Hill Protest Zone
CityBldr CEO Bryan Copley contracted COVID-19 in March and recovered while simultaneously managing his eight-person Seattle startup, which sits in the midst of the city's protest zone; his company has raised $6 million and his account illustrates the personal and business strains of the pandemic and social unrest.
Sana Biotechnology raises over $700M (SEC filings suggest $866.8M total) to advance gene and cell therapies
Sana Biotechnology announced it has raised more than $700 million in venture funding to develop gene- and cell-therapy approaches, marking one of the largest life-sciences venture rounds and among Seattles biggest. SEC filings indicate total capital and non-cash assets may total about $866.8 million, though the company declined to disclose valuation.
University of Washington Football to Test Vicis' $1,500 ZERO1 Helmet for Enhanced Brain Protection in 2016
The University of Washington football team will test Vicis' new high-tech ZERO1 helmet, designed to better protect against concussions and brain injuries, retailing at $1,500 each. Vicis, a Seattle startup spun out of UW, has garnered interest from numerous NFL and NCAA teams for the 2016 season.
